Predictive Factors for Rheumatoid Arthritis Flare After Switching From Intravenous to Subcutaneous Formulation of Tocilizumab in Real-World Practice.

Soo Min Ahn Ji-Seon Oh Hyun Mi Heo Seokchan Hong Chang-Keun Lee Bin Yoo Yong-Gil Kim

Published in: Journal of Korean medical science (2022)

MTX non-use and high dose of TCZ-IV per weight were associated with a risk of RA flare after switching to TCZ-SC. RA patients with these factors need to be carefully observed for flare after switching from TCZ-IV to TCZ-SC.

Keyphrases

rheumatoid arthritis
high dose
disease activity
ankylosing spondylitis
interstitial lung disease
low dose
stem cell transplantation
healthcare
primary care
rheumatoid arthritis patients
physical activity
drug delivery